Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Mimedx (MDXG) over the last 10 years, with Q3 2025 value amounting to $2.1 million.

  • Mimedx's Asset Writedowns and Impairment rose 83691.76% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 32288.73%. This contributed to the annual value of $595000.0 for FY2024, which is 5893.72% down from last year.
  • Per Mimedx's latest filing, its Asset Writedowns and Impairment stood at $2.1 million for Q3 2025, which was up 83691.76% from $351000.0 recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Asset Writedowns and Impairment peaked at $2.2 million during Q2 2022, and registered a low of -$279000.0 during Q3 2024.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $351000.0 (2025), whereas its average is $525866.7.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 2363333.33% in 2023, then tumbled by 16241.61% in 2024.
  • Quarter analysis of 5 years shows Mimedx's Asset Writedowns and Impairment stood at $100000.0 in 2021, then crashed by 97.0% to $3000.0 in 2022, then skyrocketed by 23633.33% to $712000.0 in 2023, then plummeted by 36.24% to $454000.0 in 2024, then skyrocketed by 352.86% to $2.1 million in 2025.
  • Its Asset Writedowns and Impairment was $2.1 million in Q3 2025, compared to $351000.0 in Q2 2025 and $742000.0 in Q1 2025.